Research advances in areas such as genomics and other “omics” (e.g., proteomics, metabolomics) have provided new opportunities to deepen our understanding of heart, lung, blood, and sleep (HLBS) pathobiological processes and how these vary among individual patients. Accelerating progress toward precise, individualized prevention efforts and medical interventions will require research into biological factors, environmental exposures, and other influences that account for differences in pathobiology and unique responses to treatment (including drug reactions and other adverse events). This research will allow personal and clinical decisions, practices, and medical products to be tailored to the individual patient to help optimize outcomes.
Envision a future in which we are able to...
- Develop precise clinical interventions based on individual environmental exposures, behaviors, genotypes, and molecular-cellular phenotypes.
- Accelerate the incorporation of new imaging, omics, and sensor technologies with advanced data analytics to inform more precise clinical classification of chronic diseases (e.g., asthma, pulmonary fibrosis, chronic obstructive lung disease, heart failure) and thereby enable more accurate diagnosis and treatment.
Last Updated: August 10, 2016